#TITLE_ALTERNATIVE#

INH and rifampicin are the primary combination used in tuberculosis treatment. However, this combination causes interactions in the gastric fluid resulting a decrease in rifampicin's bioavaibility. The purpose of the research was to formulate enteric coated INH pellets. INH pellets were prepare...

Full description

Saved in:
Bibliographic Details
Main Author: M. MALAU (NIM 10704020), FRISKA
Format: Final Project
Language:Indonesia
Online Access:https://digilib.itb.ac.id/gdl/view/10473
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Institut Teknologi Bandung
Language: Indonesia
id id-itb.:10473
spelling id-itb.:104732009-04-14T14:59:36Z#TITLE_ALTERNATIVE# M. MALAU (NIM 10704020), FRISKA Indonesia Final Project INSTITUT TEKNOLOGI BANDUNG https://digilib.itb.ac.id/gdl/view/10473 INH and rifampicin are the primary combination used in tuberculosis treatment. However, this combination causes interactions in the gastric fluid resulting a decrease in rifampicin's bioavaibility. The purpose of the research was to formulate enteric coated INH pellets. INH pellets were prepared by extrusion-spheronization method using Avicel PH 101 as filler, PVP as binder, and sodium lauryl sulfate as granulating liquid. Kollicoat MAE 30DP was used as enteric coated material. HPMC with various viscosity was applied as seal coat prior to enteric coat to improve stability of enteric coat in acid. Kollicoat with weight gain (WG) up to 60% could only prevent INH release in acid down to 26.64%. The application of HPMC 50 cps with weight gain (WG) 2, 6, and 10% before enteric coated with WG 60% resulted in a delay in INH release 6.52%, 5.70%, and 3.63%, respectively, after 2 h in gastric condition. HPMC with viscosity of 6 and 15 cps with WG 10% were able to decrease INH release in acid to 4.12% and 3.54%, respectively. In alkaline condition, INH release from enteric coated pellets was >90% in 45 min. HPMC with lower viscosity eased the coating process. Enteric coated INH pellets prepared using HPMC (WG 10%) as seal coat material and Kollicoat MAE 30DP (WG 60%) as enteric polymer resulted in a release of INH < 5% in gastric condition. Various viscosity of HPMC showed similar results in retarding INH release in gastric condition and in the release of INH in alkaline condition. text
institution Institut Teknologi Bandung
building Institut Teknologi Bandung Library
continent Asia
country Indonesia
Indonesia
content_provider Institut Teknologi Bandung
collection Digital ITB
language Indonesia
description INH and rifampicin are the primary combination used in tuberculosis treatment. However, this combination causes interactions in the gastric fluid resulting a decrease in rifampicin's bioavaibility. The purpose of the research was to formulate enteric coated INH pellets. INH pellets were prepared by extrusion-spheronization method using Avicel PH 101 as filler, PVP as binder, and sodium lauryl sulfate as granulating liquid. Kollicoat MAE 30DP was used as enteric coated material. HPMC with various viscosity was applied as seal coat prior to enteric coat to improve stability of enteric coat in acid. Kollicoat with weight gain (WG) up to 60% could only prevent INH release in acid down to 26.64%. The application of HPMC 50 cps with weight gain (WG) 2, 6, and 10% before enteric coated with WG 60% resulted in a delay in INH release 6.52%, 5.70%, and 3.63%, respectively, after 2 h in gastric condition. HPMC with viscosity of 6 and 15 cps with WG 10% were able to decrease INH release in acid to 4.12% and 3.54%, respectively. In alkaline condition, INH release from enteric coated pellets was >90% in 45 min. HPMC with lower viscosity eased the coating process. Enteric coated INH pellets prepared using HPMC (WG 10%) as seal coat material and Kollicoat MAE 30DP (WG 60%) as enteric polymer resulted in a release of INH < 5% in gastric condition. Various viscosity of HPMC showed similar results in retarding INH release in gastric condition and in the release of INH in alkaline condition.
format Final Project
author M. MALAU (NIM 10704020), FRISKA
spellingShingle M. MALAU (NIM 10704020), FRISKA
#TITLE_ALTERNATIVE#
author_facet M. MALAU (NIM 10704020), FRISKA
author_sort M. MALAU (NIM 10704020), FRISKA
title #TITLE_ALTERNATIVE#
title_short #TITLE_ALTERNATIVE#
title_full #TITLE_ALTERNATIVE#
title_fullStr #TITLE_ALTERNATIVE#
title_full_unstemmed #TITLE_ALTERNATIVE#
title_sort #title_alternative#
url https://digilib.itb.ac.id/gdl/view/10473
_version_ 1820664984300945408